 This study investigates the effects of microRNA-1286-MIR-1286 on non-small cell lung cancer, nsclc, development by the aerobic glycolysis pathway by targeting pyruvate kinase muscle isozyme M2, PKM2. The results show that MIR-1286 inhibits A549 cell proliferation in vitro and suppresses the growth of A549 cells in vivo, with PKM2 being the target gene of MIR-1286. These findings suggest that MIR-1286 can be a promising predictive biomarker and potential therapeutic target for nsclc. This article was authored by Huili, Shua-Shellen, Chao-Pung-Li, and others.